Regeneracinė medicina - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | - | - | - | - | - | 290,000 | 1,760,000 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | -37 | 0 | 0 | 0 | 0 | 0 | 268,818 | 1,383,998 |
| Equity | 2,758 | 2,758 | 2,758 | 2,758 | 2,758 | 2,758 | 271,575 | 1,655,573 |
| Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 28,999 | 337,197 |
| Non-current assets | 840 | 840 | 840 | 840 | 840 | 840 | 0 | 0 |
| Current assets | 1,918 | 1,918 | 1,918 | 1,918 | 1,918 | 1,918 | 300,574 | 1,992,770 |
| Total assets | 2,758 | 2,758 | 2,758 | 2,758 | 2,758 | 2,758 | 300,574 | 1,992,770 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | - | 47,899 | 359,046 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | - | - | - | - | - | +506.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -1.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 89.4% | 69.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -1.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 99.0% | 83.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | - | - | 92.7% | 78.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | 0.1 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - | 290,000 | 1,173,333 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Regeneracinė medicina - Social security debts
The company had no debts to Sodra
Regeneracinė medicina - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2024-11-17 | 2024-11-18 | 5.67 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Regeneracine medicina, UAB (code 303341853) is a Private Limited Liability Company engaged in business and other management consultancy activities. In 2025, the company generated revenue of €1.76M and net profit of €1.38M, which corresponds to a profit margin of 78.6%. Revenue increased by 506.9% year on year, showing a very strong expansion compared with 2024, when revenue was €290.0K and net profit was €268.8K. Profit also rose sharply over the same period, while the margin remained high, though lower than the 92.7% reported in 2024. The balance sheet strengthened alongside growth: total assets reached €1.99M at the end of 2025, compared with €300.6K a year earlier, and equity increased to €1.66M from €271.6K. Liabilities rose to €337.2K, but debt remained modest relative to equity, with a debt-to-equity ratio of 0.20. Key efficiency indicators were also strong in 2025, with return on equity at 83.6%, return on assets at 69.5%, and asset turnover at 0.88x. Revenue per employee was €1.76M, indicating high productivity.